The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Lead Researcher Discusses Anti-PD-L1 Agent Avelumab in Ovarian Cancer
August 18th 2015Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.
Molecular Imaging May Help Tailor Breast Cancer Therapies
August 13th 2015Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.
Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian Cancer
August 11th 2015Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.
Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer
August 10th 2015Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.
Telotristat Etiprate Cuts Carcinoid Syndrome-Related Diarrhea in Phase III Study
August 3rd 2015Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.
Immune Checkpoint Combination Strategies Evolving in NSCLC
August 1st 2015A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.
Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer
July 31st 2015The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.
Researcher Responsible for CLL Breakthroughs Honored by ASH
July 31st 2015John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.